Centessa Pharmaceuticals PLC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Farallon Capital Management and associated individuals have reported the disposal of their entire stake in Centessa Pharmaceuticals following its acquisition by Eli Lilly.
NASDAQ
Farallon Capital Management has filed a Schedule 13D reporting a 6.1% beneficial ownership stake in Centessa Pharmaceuticals plc.
NASDAQ
SCHEDULE 13D/A: General Atlantic Exits Centessa Pharmaceuticals Stake
General Atlantic and its affiliated entities have filed an exit amendment to their Schedule 13D, reporting their beneficial ownership in Centessa Pharmaceuticals plc has fallen below 5% after recent open market sales.
NASDAQ
General Atlantic entities have filed an amended Schedule 13D, disclosing a plan to sell up to 3.5 million Centessa Pharmaceuticals ADSs.